Table 1.
Baseline characteristics of the study participants, by catheter patency.
| Characteristic | Overall (N = 124) |
Catheter Group |
p Value |
|
|---|---|---|---|---|
| Patent (N = 93) |
Non-Patent (N = 31) |
|||
| Age (median [range] years) | 72.0 [26–93] | 69.0 [26–93] | 75.0 [50–92] | 0.003 |
| Sex [n (%)] | ||||
| Men | 68 (54.8) | 54 (58.1) | 14 (45.2) | 0.214 |
| Women | 56 (45.2) | 39 (41.9) | 17 (54.8) | |
| Comorbidities [n (%)] | ||||
| Diabetes mellitus | 89 (71.8) | 69 (74.2) | 20 (64.5) | 0.304 |
| Hypertension | 96 (77.4) | 68 (73.1) | 28 (90.3) | 0.048 |
| Heart failure | 41 (33.1) | 31 (33.3) | 10 (32.3) | 0.913 |
| Ischemic heart disease | 34 (27.4) | 28 (30.1) | 6 (19.4) | 0.249 |
| Atrial fibrillation | 24 (19.4) | 15 (16.1) | 9 (29.0) | 0.117 |
| Cerebral infarction | 19 (15.3) | 10 (10.8) | 9 (29.0) | 0.014 |
| Liver cirrhosis | 6 (4.8) | 1 (1.1) | 5 (16.1) | 0.001 |
| Medication [n (%)] | ||||
| Aspirin | 29 (23.4) | 20 (21.5) | 9 (29.0) | 0.395 |
| Clopidogrel | 33 (26.6) | 24 (25.8) | 9 (29.0) | 0.727 |
| Warfarin | 6 (4.8) | 3 (3.2) | 3 (9.7) | 0.150 |
| Cilostazol | 7 (5.6) | 5 (5.4) | 2 (6.5) | 0.824 |
| NOAC | 8 (6.5) | 6 (6.5) | 2 (6.5) | 1.000 |
| Statin | 61 (49.2) | 46 (49.5) | 15 (48.4) | 0.918 |
| Laboratory data (median [range]) | ||||
| Hemoglobin (g/dL) | 9.6 [4.8–14.4] | 9.5 [4.8–16.1] | 9.9 [6.1–13.0] | 0.158 |
| Total lymphocyte count (103/µL) | 1160.0 [240–11,390] | 1270.0 [240–11,390] | 1000.0 [340–3220] | 0.254 |
| Platelet (000s) | 189.0 [12–820] | 191.0 [12–820] | 167.0 [20–329] | 0.221 |
| CRP (mg/dL) | 1.8 [0.1–40] | 1.1 [0.1–40] | 6.7 [0.1–40] | 0.003 |
| Total protein (g/dL) | 6.1 [4.1–8.4] | 6.1 [3.2–8.4] | 5.9 [4.1–7.9] | 0.383 |
| Albumin (g/dL) | 3.0 [1.6–4.4] | 3.0 [1.5–4.4] | 2.8 [1.6–3.8] | 0.009 |
| BUN (mg/dL) | 54.3 [11.9–177.8] | 53.0 [13.9–184] | 54.9 [11.9–143.4] | 0.944 |
| Creatinine (mg/dL) | 4.8 [0.7–31.4] | 5.1 [0.7–32.9] | 4.3 [0.9–11.7] | 0.021 |
| Total cholesterol (mg/dL) | 127.0 [45–494] | 126.0 [45–494] | 135.0 [52–290] | 0.835 |
| Total calcium (mg/dL) | 7.7 [5.0–10.5] | 7.7 [5.0–10.4] | 7.7 [5.3–10.5] | 0.330 |
| Phosphorus (mg/dL) | 4.2 [1.5 –12.6] | 4.1 [1.5–12.6] | 4.2 [1.7–9.9] | 0.606 |
| Sodium (mEq/L) | 136.5 [122–153.6] | 136.6 [122–153] | 136.4 [124–153.6] | 0.471 |
| Potassium (mEq/L) | 4.3 [2.8–7.8] | 4.3 [2.8–7.8] | 4.3 [2.8–6.2] | 0.976 |
| BMI (kg/m2) | 23.5 [15.1–41.9] | 23.4 [15.1–41.9] | 25.0 [16.0–39.2] | 0.339 |
| Body composition (median [range]) | ||||
| ECW (L) | 16.2 [8.4–32.5] | 17.4 [8.4–32.5] | 12.2 [10.3–30.7] | 0.371 |
| ICW (L) | 15.3 [7.8–28.0] | 15.8 [7.9–28.0] | 12.5 [7.8–22.2] | 0.000 |
| TBW (L) | 31.8 [16.3–56.4] | 33.8 [16.3–56.4] | 27.7 [19.7–52.9] | 0.013 |
| ECW/ICW ratio | 1.13 [0.62–1.90] | 1.05 [0.62–1.89] | 1.22 [0.87–1.78] | 0.001 |
| LTI (kg/m2) | 11.6 [5.3–21.4] | 12.4 [5.8–21.4] | 9.4 [5.3–16.4] | 0.000 |
| FTI (kg/m2) | 10.7 [0.9–29.8] | 9.7 [0.9–29.0] | 11.2 [2.1–29.8] | 0.042 |
| LTM (kg) | 28.2 [2.0–59.3] | 30.7 [2.0–59.3] | 22.9 [12.5–51.3] | 0.013 |
| ATM (kg) | 24.8 [2.3–66.9] | 24.0 [2.3–64.5] | 29.5 [2.4–66.9] | 0.222 |
| FAT (kg) | 18.4 [1.7–49.2] | 17.6 [1.7–47.4] | 21.7 [4.9–49.2] | 0.042 |
| Body cell mass | 15.4 [2.3–36.1] | 16.8 [2.3–36.1] | 11.7 [4.1–29.6] | 0.001 |
| Dry weight (kg) | 57.6 [33.5–99.7] | 58.5 [33.5–99.7] | 53.3 [37.2–90.9] | 0.228 |
| Information of initiating hemodialysis (median [range]) | ||||
| Blood flow rate (mL/min) | 200 [180–250] | 200 [180–250] | 220 [180–250] | 0.370 |
| Dialysis duration (h) | 2.0 [1.0–4.0] | 2.0 [1.0–4.0] | 3.0 [2.0–4.0] | 0.202 |
| Ultrafiltration volume (L) | 1.5 [0.2–4.0] | 1.5 [0.3–4.0] | 1.7 [0.2–4.0] | 0.421 |
NOAC: non-vitamin K antagonist oral anticoagulant; CRP: C-reactive protein; BUN: blood urea nitrogen; BMI: body mass index; ECW: extracellular water; ICW: intracellular water; TBW: total body water; LTI: lean tissue index; FTI: fat tissue index; LTM: lean tissue mass; ATM: adipose tissue mass; FAT: fat mass.